Switzerland
Swiss patients face unequal access to life-saving treatment
An RTS investigation has found wide disparities in Swiss insurance coverage for some life-saving treatments prescribed off label. The investigation warns that access may worsen as the launch of new drugs in Switzerland faces growing delays.

Nearly 80,000 applications were submitted last year in Switzerland for medicines not automatically covered by basic health insurance. Behind those requests sits a system in which a patient’s access to a prescribed treatment can depend on the insurer assessing the case.
An RTS investigation found sharp differences in how insurers decide whether to reimburse medicines prescribed outside their approved indications, or medicines that lack an agreed Swiss price. Some insurers accept almost all requests. Others reject more than half.
The findings draw on data behind a government-commissioned report from 2020. RTS obtained the information after a legal battle with the Federal Office of Public Health (FOPH). The investigation lands as the launch of new medicines in Switzerland faces growing delays. Together, the uneven decisions and slower arrivals raise concern that access to new treatments could increasingly depend on a patient’s insurer and on whether a medicine has reached the Swiss market.
Map the rules behind exceptional coverage
Basic insurance does not automatically cover every medicine a doctor may prescribe. The FOPH Specialities List determines which medicines are reimbursed, and coverage applies when a listed drug is used for its intended indication. Treatments outside those rules require an exceptional decision.
Articles 71a to 71d of the Health Insurance Ordinance allow insurers to consider three situations: a listed medicine used for a different condition; a medicine authorised in Switzerland but not on the Specialities List; or a medicine not authorised in Switzerland but approved for the relevant use in a recognised country.
Doctors must submit a request to the insurer. The insurer consults its medical adviser and assesses the case individually. Reimbursement requires a serious illness, significant therapeutic benefit and no other effective, reimbursed treatment. That case-by-case process can be especially relevant in oncology, where treatment is becoming more personalised. The rules set conditions for access, but RTS found that insurers apply them with markedly different outcomes.
Track the path of a pancreatic cancer drug
Daraxonrasib shows what can be at stake when a new treatment reaches countries at different speeds. The drug, developed by US biotech company Revolution Medicines, was approved by the US Food and Drug Administration for advanced pancreatic cancer on August 26. It became widely available in the United States after approval.
The treatment targets mutated KRAS proteins, which are responsible for more than 90% of pancreatic cancers. In clinical trials, daraxonrasib doubled median survival time for patients with metastatic pancreatic cancer. Its trial results drew a rare standing ovation at a major US cancer congress in May.
Switzerland’s route is different. Revolution Medicines, which established its European headquarters in Basel in 2025, submitted an application to Swissmedic on August 19. Swissmedic approval would be only one step in the process described in the investigation: reimbursement still depends on the applicable Swiss rules. Until medicines enter the standard system, patients and doctors may have to seek exceptional coverage from their insurer.
Watch how delays reshape access
New-drug launch delays could deepen the access divide. The RTS investigation warns that the problem may worsen as life-saving medicines take longer to launch in Switzerland. When a treatment is not yet part of the standard reimbursement system, patients may depend on the exceptional process and the decision of their own insurer.
That process is designed for medicines outside routine coverage, including off-label use and treatments without an agreed price. It requires doctors to make a case for significant benefit in a serious illness when no effective reimbursed alternative is available. But the investigation’s findings show that insurers do not reach uniform decisions: some approve nearly every request, while others refuse more than half.
The result is a system in which access can vary even when a doctor seeks treatment under the same national rules. For patients with serious illnesses, the timing of a medicine’s arrival and the insurer’s assessment can both shape whether a promising therapy is within reach. The debate now concerns how Switzerland handles exceptional reimbursement as new treatments arrive later.